Weight Management Implant
Novo Nordisk and Vivani Plan Mid-2026 Trial for Semaglutide Weight-Loss Implant
Key Points
NPM-139 is described as roughly the size of a matchstick and is intended to deliver semaglutide for up to six months, with a longer-term goal of a year-long version.
The Phase 1 trial is planned as randomized and first-in-human, expected to start in mid-2026, with Wegovy injections as an active comparator to assess safety, pharmacokinetics and tolerability, aiming to support a Phase 2 dose-ranging study.
Novo Nordisk will conduct a non-exclusive internal evaluation of the semaglutide implants, with no exclusivity provisions or licensing tied to the agreement; the arrangement is described as a look rather than a formal partnership.
The deal is situated in the broader context of expanding access to GLP-1 therapies, with Wegovy currently supported by Medicare's GLP-1 Bridge program (about a $50 copay for eligible patients), highlighting the competitive landscape Novo Nordisk is navigating.
Novo Nordisk has agreed to evaluate a matchstick-sized semaglutide implant that could replace weekly Wegovy injections with a single device lasting up to six months. The implant, called NPM-139, is made by California-based Vivani Medical and uses the company's NanoPortal platform to slowly release the drug over time, according to Pharmaceutical Technology.
A first-in-human Phase 1 trial is planned to begin in mid-2026. The study will compare NPM-139 directly against Wegovy injections, testing safety, drug levels in the blood, and tolerability. If successful, a Phase 2 dose-ranging study could follow, Healthcare Digital reported.
What the Implant Is and How It Works
NPM-139 is roughly the size of a matchstick. It sits under the skin and releases semaglutide — the active ingredient in Wegovy — continuously for up to six months. Vivani's goal is eventually a version that lasts a full year. The device uses the company's NanoPortal platform, a drug-delivery technology built for slow, steady release of medicines over long periods.
Vivani's leadership says the implant targets patients who want a more convenient option. Rather than a weekly shot or daily pill, patients could get one or two implants per year. The device can also be removed if a patient needs to stop treatment, giving doctors and patients a way to reverse the therapy quickly.
Novo Nordisk Takes a Look, Not a Partnership
The agreement gives Novo Nordisk the right to run its own internal evaluation of NPM-139. Crucially, the deal comes with no licensing, no exclusive rights, and no formal partnership. Market Screener described the arrangement as a non-exclusive look — Novo Nordisk can study the implant, but Vivani keeps full control of the technology.
Still, the deal signals real interest from one of the world's biggest drugmakers in implant-based GLP-1 delivery. GLP-1 refers to a class of drugs, including semaglutide, that suppress appetite and lower blood sugar. Novo Nordisk already dominates this space with Wegovy and Ozempic, but faces growing competition as the obesity drug market rapidly expands.
The 2026 Trial: What Patients and Investors Should Know
The Phase 1 study is designed as a randomized, first-in-human trial. Participants will receive either NPM-139 or Wegovy injections. Researchers will measure how much drug enters the bloodstream, how safe the implant is, and how well patients tolerate it. The trial is planned to start in mid-2026, according to Vivani Medical's announcement via Market Screener.
If Phase 1 data looks good, a Phase 2 dose-ranging study could follow. That study would test different doses to find the most effective level. Both trials together would help determine whether NPM-139 can match or exceed the performance of weekly injections in real-world weight loss treatment.
Competitive Pressure Pushes Novo Nordisk Toward New Formats
Novo Nordisk is navigating a crowded market. Wegovy is currently available through Medicare's GLP-1 Bridge program for about a $50 copay for eligible patients. Rival companies are racing to develop oral pills, longer-acting injections, and now implants. Exploring new delivery formats helps Novo Nordisk defend its position as the market leader.
For Vivani, the Novo Nordisk evaluation is a major vote of confidence. The California company is still in early stages, with no approved products yet. A successful Phase 1 trial in 2026, backed by data comparing directly to Wegovy, could open the door to larger partnerships — or attract other big pharma players to the NanoPortal platform.
Sentiment
Mostly PositivePublishers
13
Articles
36
Reach
49
